242 related articles for article (PubMed ID: 16033823)
1. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival.
Tommiska J; Eerola H; Heinonen M; Salonen L; Kaare M; Tallila J; Ristimäki A; von Smitten K; Aittomäki K; Heikkilä P; Blomqvist C; Nevanlinna H
Clin Cancer Res; 2005 Jul; 11(14):5098-103. PubMed ID: 16033823
[TBL] [Abstract][Full Text] [Related]
2. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L
Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738
[TBL] [Abstract][Full Text] [Related]
5. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
6. P53 codon 72 polymorphism in breast cancer.
Buyru N; Tigli H; Dalay N
Oncol Rep; 2003; 10(3):711-4. PubMed ID: 12684648
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
[TBL] [Abstract][Full Text] [Related]
8. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
[TBL] [Abstract][Full Text] [Related]
9. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
11. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
12. Her2 genotype and breast cancer progression in Korean women.
An HJ; Kim NK; Oh D; Kim SH; Park MJ; Jung MY; Kang H; Kim SG; Lee KP; Lee KS
Pathol Int; 2005 Feb; 55(2):48-52. PubMed ID: 15693849
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis.
Jin Q; Hemminki K; Enquist K; Lenner P; Grzybowska E; Klaes R; Henriksson R; Chen B; Pamula J; Pekala W; Zientek H; Rogozinska-Szczepka J; Utracka-Hutka B; Hallmans G; Försti A
Clin Cancer Res; 2005 May; 11(10):3647-53. PubMed ID: 15897560
[TBL] [Abstract][Full Text] [Related]
15. Association of cyclin D1 genotype with breast cancer risk and survival.
Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
[TBL] [Abstract][Full Text] [Related]
16. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population.
Franeková M; Zúbor P; Stanclová A; Dussan CA; Bohusová T; Galo S; Dobrota D; Kajo K; Péc M; Racay P
Neoplasma; 2007; 54(2):155-61. PubMed ID: 17319790
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women.
Noma C; Miyoshi Y; Taguchi T; Tamaki Y; Noguchi S
Cancer Lett; 2004 Jul; 210(2):197-203. PubMed ID: 15183535
[TBL] [Abstract][Full Text] [Related]
18. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
Sullivan PS; Apple SK
Breast J; 2009; 15(2):146-54. PubMed ID: 19292800
[TBL] [Abstract][Full Text] [Related]
19. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women.
Zubor P; Lasabova Z; Hatok J; Stanclova A; Danko J
Oncol Rep; 2007 Jul; 18(1):211-7. PubMed ID: 17549370
[TBL] [Abstract][Full Text] [Related]
20. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
